Miguel Gouveia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Miguel Gouveia has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
João Costa
B Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina , Universidade de Lisboa , Lisboa , Portugal
13 shared publications- Margarida Borges
Evidence-Based Medicine Centre for Studies, Lisbon University School of Medicine
10 shared publications - António Vaz Carneiro
Comissão Para a Inteligência Artificial. Ordem dos Médicos. Lisboa. & Instituto de Saúde Baseada na Evidência. Lisboa. & Choosing Wisely Portugal. Lisboa
9 shared publications Margarida Borges
B Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina , Universidade de Lisboa , Lisboa , Portugal
7 shared publications- Eduardo Infante de Oliveira
Cardiology Department, Centro Hospitalar de Lisboa Ocidental, Portugal; Cardiology Department, Lisbon Lusiadas Hospital, Portugal; Institute of Physiology, Faculty of Medicine, University of Lisbon, Portugal
4 shared publications Margarida Augusto
4 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Elsevier in Games and Economic Behavior
- Vol. 159, 604-624
On the political economy of nonlinear income taxation
- 21 August 2026
- Published by Elsevier in Games and Economic Behavior
- Vol. 159, 604-624
Open AccessOn the political economy of nonlinear income taxation
- Open Access
- 17 December 2025
- Published by Springer Nature in Public Choice
- Vol. 207 (3-4) , 321-340
Does the US individual income tax display systemic racism? Negative evidence from audited US federal tax return data for 1967–73
Official statistics from the US Bureau of Labor Statistics and the US Bureau of the Census have long documented differences by ethnicity in employment rates and incomes. Recently, it has been suggested that the structure of the US federal individual tax system is 'systemically racist' which we interpret to mean that the application of the Internal Revenue Code through collection of individual income taxes adversely affects African American compared to White individuals and households. This paper contributes to the public discussion of possible systemic racism in the US tax system issue by studying an unusual set of US individual income tax data. These data differ from those used in other studies in two important ways. First, race is not imputed but obtained from the administrative records of the Social Security Administration. Second, the income tax data are audited tax return data. Using these audited and administratively matched data, we estimate effective income tax functions with an explicit role for race. After accounting for the basic structure of the US tax system, we find no statistical evidence of systemic racism in the operation of the US federal individual income tax during the period under study. Our results show that once income and filing status are taken into account, the effective tax rate tax did not vary by race—a finding that remains robust across multiple checks.
- 17 December 2025
- Published by Springer Nature in Public Choice
- Vol. 207 (3-4) , 321-340
Open AccessDoes the US individual income tax display systemic racism? Negative evidence from audited US federal tax return data for 1967–73
Official statistics from the US Bureau of Labor Statistics and the US Bureau of the Census have long documented differences by ethnicity in employment rates and incomes. Recently, it has been suggested that the structure of the US federal individual tax system is 'systemically racist' which we interpret to mean that the application of the Internal Revenue Code through collection of individual income taxes adversely affects African American compared to White individuals and households. This paper contributes to the public discussion of possible systemic racism in the US tax system issue by studying an unusual set of US individual income tax data. These data differ from those used in other studies in two important ways. First, race is not imputed but obtained from the administrative records of the Social Security Administration. Second, the income tax data are audited tax return data. Using these audited and administratively matched data, we estimate effective income tax functions with an explicit role for race. After accounting for the basic structure of the US tax system, we find no statistical evidence of systemic racism in the operation of the US federal individual income tax during the period under study. Our results show that once income and filing status are taken into account, the effective tax rate tax did not vary by race—a finding that remains robust across multiple checks.
- Open Access
- 1 February 2021
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 40 (2) , 117-118
Indirect costs associated with cardiovascular events in Portugal
- 1 February 2021
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 40 (2) , 117-118
Open AccessIndirect costs associated with cardiovascular events in Portugal
- 20 February 2019
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 15 (4) , 850-858
Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
The burden of pneumococcal disease in adults is substantial from a social and economic point of view. This study assessed the cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23). A Markov model was used to simulate three strategies: no vaccination, complete vaccination with PPSV23 and complete vaccination with PCV13. The comparison between strategies allowed the estimation of clinical and economic outcomes including incremental cost-effectiveness ratios (ICER) and incremental cost-utility ratios (ICUR). The model took into account the distributions of age, risk profile, vaccination status, type of immunization and time since vaccination in the population. A societal perspective was adopted and a lifetime horizon was considered. Different sources of data and assumptions were used to calibrate PPSV23 and PCV13 effectiveness. Inpatient costs were based on the 2013 diagnosis-related group (DRG) database for National Health Service (NHS) hospitals and expert opinion; NHS official tariffs were the main source for unitary costs. PCV13 shows ICURs of €17,746/QALY and €13,146/QALY versus “no vaccination” and vaccination with PPSV23, respectively. Results proved to be robust in univariate sensitivity analyses, where all ratios were below a €20,000 threshold, with the exception of the scenario with PCV13 effectiveness halved. In a probabilistic sensitivity analysis, 94% of simulations showed cost-effectiveness ratios lower than €20,000/QALY, in both strategies. It was found that PCV13 is a cost-effective strategy to prevent pneumococcal disease in adults in Portugal.
- 20 February 2019
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 15 (4) , 850-858
Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
The burden of pneumococcal disease in adults is substantial from a social and economic point of view. This study assessed the cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23). A Markov model was used to simulate three strategies: no vaccination, complete vaccination with PPSV23 and complete vaccination with PCV13. The comparison between strategies allowed the estimation of clinical and economic outcomes including incremental cost-effectiveness ratios (ICER) and incremental cost-utility ratios (ICUR). The model took into account the distributions of age, risk profile, vaccination status, type of immunization and time since vaccination in the population. A societal perspective was adopted and a lifetime horizon was considered. Different sources of data and assumptions were used to calibrate PPSV23 and PCV13 effectiveness. Inpatient costs were based on the 2013 diagnosis-related group (DRG) database for National Health Service (NHS) hospitals and expert opinion; NHS official tariffs were the main source for unitary costs. PCV13 shows ICURs of €17,746/QALY and €13,146/QALY versus “no vaccination” and vaccination with PPSV23, respectively. Results proved to be robust in univariate sensitivity analyses, where all ratios were below a €20,000 threshold, with the exception of the scenario with PCV13 effectiveness halved. In a probabilistic sensitivity analysis, 94% of simulations showed cost-effectiveness ratios lower than €20,000/QALY, in both strategies. It was found that PCV13 is a cost-effective strategy to prevent pneumococcal disease in adults in Portugal.
- 18 February 2019
- Published by Wiley in Population and Development Review
- Vol. 45 (2) , 401-418
Aging and the Compression of Disability in Portugal
- 18 February 2019
- Published by Wiley in Population and Development Review
- Vol. 45 (2) , 401-418
Aging and the Compression of Disability in Portugal
- 1 October 2018
- Published by Elsevier in Value in Health
- Vol. 21, S104
PCV71 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
- 1 October 2018
- Published by Elsevier in Value in Health
- Vol. 21, S104
PCV71 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
- 1 August 2017
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 36 (8) , 782-787
Cost-effectiveness of the 13-valent Pneumococcal Conjugate Vaccine in Children in Portugal
Pneumococcal infections are the leading cause of vaccine-preventable death in children. In June 2015, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the Portuguese Immunization Program. We evaluate the cost-effectiveness of children vaccination with PCV13 versus no vaccination for preventing pneumococcal diseases (PD). A cohort simulation model for 2014 Portuguese newborns was used, considering a lifetime horizon and existence of herd effect on adults. Model outcomes measured life years gained (LYG), direct and indirect healthcare costs and net benefits considering €20,000 per LYG. PCV13 clinical effectiveness rate by serotype covered was assumed similar to PCV7. Patients’ resource use was based on 2014 diagnostic-related-group database and experts’ opinion, while national legislation and official drug cost database were the main sources for unitary costs. Univariate sensitivity analyses were conducted to assess results’ effectiveness. In base case scenario, PCV13 was a dominant strategy, being associated with better health outcomes and lower costs. In a lifetime, a total of 6,238 infections (excluding AOM) and 130 deaths were averted, with a total saving of €397,217 (USD $432,966). Net benefits were estimated above €28M (USD $30M.) Results were robust in all sensitivity analyses, with positive net benefits, except when herd effect was excluded. Vaccination of children with PCV13 starting in their first year of life is a cost-effective intervention with the potential to save costs to the Portuguese health system and to provide health gains by reducing the burden of pneumococcal disease in the vaccinees and through the herd effect of this vaccine.
- 1 August 2017
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 36 (8) , 782-787
Cost-effectiveness of the 13-valent Pneumococcal Conjugate Vaccine in Children in Portugal
Pneumococcal infections are the leading cause of vaccine-preventable death in children. In June 2015, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the Portuguese Immunization Program. We evaluate the cost-effectiveness of children vaccination with PCV13 versus no vaccination for preventing pneumococcal diseases (PD). A cohort simulation model for 2014 Portuguese newborns was used, considering a lifetime horizon and existence of herd effect on adults. Model outcomes measured life years gained (LYG), direct and indirect healthcare costs and net benefits considering €20,000 per LYG. PCV13 clinical effectiveness rate by serotype covered was assumed similar to PCV7. Patients’ resource use was based on 2014 diagnostic-related-group database and experts’ opinion, while national legislation and official drug cost database were the main sources for unitary costs. Univariate sensitivity analyses were conducted to assess results’ effectiveness. In base case scenario, PCV13 was a dominant strategy, being associated with better health outcomes and lower costs. In a lifetime, a total of 6,238 infections (excluding AOM) and 130 deaths were averted, with a total saving of €397,217 (USD $432,966). Net benefits were estimated above €28M (USD $30M.) Results were robust in all sensitivity analyses, with positive net benefits, except when herd effect was excluded. Vaccination of children with PCV13 starting in their first year of life is a cost-effective intervention with the potential to save costs to the Portuguese health system and to provide health gains by reducing the burden of pneumococcal disease in the vaccinees and through the herd effect of this vaccine.
- Open Access
- 31 August 2016
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 29 (7-8) , 432-440
Embolia Pulmonar em Portugal: Epidemiologia e Mortalidade Intra-Hospitalar
Introdução: Em Portugal, a epidemiologia da embolia pulmonar aguda é mal conhecida. Neste estudo, pretendeu-se caracterizar a embolia pulmonar a partir dos dados do internamento hospitalar, assim como avaliar a sua mortalidade intra-hospitalar (definida como mortalidade do internamento hospitalar) e respetivos fatores de prognóstico.Material e Métodos: Microdados dos Grupos de Diagnóstico Homogéneo dos hospitais do Sistema Nacional de Saúde (2003 a 2013) e dados sobre população do Instituto Nacional de Estatística para estabelecer a evolução dos internamentos, da mortalidade intrahospitalar e das taxas de incidência na população. Os microdados foram estudados numa regressão logit modelizando a mortalidade intra-hospitalar como função de características individuais e de variáveis de contexto.Resultados: Entre 2003 e 2013 ocorreram 35 200 episódios de internamento (doentes ≥ 18 anos) em que pelo menos um dos diagnósticos foi embolia pulmonar (diagnóstico principal em 67% dos casos). A taxa de incidência estimada em 2013 foi 35/100 000 habitantes (≥ 18 anos). Entre 2003 e 2013, o número anual de episódios foi aumentando, mas a taxa de mortalidade intra-hospitalar foi diminuindo (de 31,8% para 17% em todos os episódios e de 25% para 11,2% nos episódio com embolia pulmonar como diagnóstico principal). Entre 2010 e 2013 a probabilidade de morte reduziu-se com a existência de registo de tomografia computorizada, em doentes do género feminino e aumentou com a idade e a presença de comorbilidades.Discussão: Na última década ocorreu um aumento da incidência de embolia pulmonar provavelmente relacionado com um maior número de pessoas dependentes e acamadas. No entanto, verificou-se uma redução da mortalidade intra-hospitalar de tal dimensão que a própria taxa de mortalidade na população em geral se reduziu. Uma explicação possível é que tenha ocorrido um aumento dos episódios de embolia pulmonar com níveis de gravidade incrementalmente menores, pela maior capacidade de diagnóstico de casos menos graves. Outra explicação possível é uma maior efetividade dos cuidados de saúde hospitalares. De acordo com a análise deregressão logística, as melhorias na efetividade dos cuidados hospitalares nos últimos anos são o principal responsável pela redução da mortalidade.Conclusão: Cerca de 79% da redução da mortalidade intra-hospitalar da embolia pulmonar entre 2003 e 2013 pode-se atribuir à maior efetividade dos cuidados de saúde hospitalares e o restante à alteração favorável nas características dos doentes associadas ao risco de morte.
- 31 August 2016
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 29 (7-8) , 432-440
Open AccessEmbolia Pulmonar em Portugal: Epidemiologia e Mortalidade Intra-Hospitalar
Introdução: Em Portugal, a epidemiologia da embolia pulmonar aguda é mal conhecida. Neste estudo, pretendeu-se caracterizar a embolia pulmonar a partir dos dados do internamento hospitalar, assim como avaliar a sua mortalidade intra-hospitalar (definida como mortalidade do internamento hospitalar) e respetivos fatores de prognóstico.Material e Métodos: Microdados dos Grupos de Diagnóstico Homogéneo dos hospitais do Sistema Nacional de Saúde (2003 a 2013) e dados sobre população do Instituto Nacional de Estatística para estabelecer a evolução dos internamentos, da mortalidade intrahospitalar e das taxas de incidência na população. Os microdados foram estudados numa regressão logit modelizando a mortalidade intra-hospitalar como função de características individuais e de variáveis de contexto.Resultados: Entre 2003 e 2013 ocorreram 35 200 episódios de internamento (doentes ≥ 18 anos) em que pelo menos um dos diagnósticos foi embolia pulmonar (diagnóstico principal em 67% dos casos). A taxa de incidência estimada em 2013 foi 35/100 000 habitantes (≥ 18 anos). Entre 2003 e 2013, o número anual de episódios foi aumentando, mas a taxa de mortalidade intra-hospitalar foi diminuindo (de 31,8% para 17% em todos os episódios e de 25% para 11,2% nos episódio com embolia pulmonar como diagnóstico principal). Entre 2010 e 2013 a probabilidade de morte reduziu-se com a existência de registo de tomografia computorizada, em doentes do género feminino e aumentou com a idade e a presença de comorbilidades.Discussão: Na última década ocorreu um aumento da incidência de embolia pulmonar provavelmente relacionado com um maior número de pessoas dependentes e acamadas. No entanto, verificou-se uma redução da mortalidade intra-hospitalar de tal dimensão que a própria taxa de mortalidade na população em geral se reduziu. Uma explicação possível é que tenha ocorrido um aumento dos episódios de embolia pulmonar com níveis de gravidade incrementalmente menores, pela maior capacidade de diagnóstico de casos menos graves. Outra explicação possível é uma maior efetividade dos cuidados de saúde hospitalares. De acordo com a análise deregressão logística, as melhorias na efetividade dos cuidados hospitalares nos últimos anos são o principal responsável pela redução da mortalidade.Conclusão: Cerca de 79% da redução da mortalidade intra-hospitalar da embolia pulmonar entre 2003 e 2013 pode-se atribuir à maior efetividade dos cuidados de saúde hospitalares e o restante à alteração favorável nas características dos doentes associadas ao risco de morte.
- Open Access
- 1 July 2015
- Published by Portuguese Society of Dermatology and Venereology in Journal of the Portuguese Society of Dermatology and Venereology
- Vol. 73 (2) , 283-286
DERMATIOMIOSITE COM DOENÇA INTERSTICIAL PULMONAR - UMA ASSOCIAÇÃO COM ANTI-MDA-5
Dermatomyositis is a systemic autoimmune disease with cutaneous, muscular and pulmonary involvement. MDA-5 has recently been described as a specific dermatomyositis target antigen associated with a higher risk for interstitial lung disease. A 54-year-old female patient presented with proximal muscular weakness, myalgia and cutaneous signs of dermatomyositis. She presented with high aldolase and CK levels, and the muscular biopsy and electromyography were consistent with dermatomyositis. Pulmonary CT scan showed ground glass appearance. Autoimmunity revealed strong anti-MDA-5 positivity. No neoplasm was detected. She began treatment with prednisolone 20mg, hydroxicloroquine 400mg and methotrexate 20mg/week with very little improvement. She then began IVIG, with better clinical response. The authors report a case of dermatomyositis with interstitial lung disease associated with anti-MDA-5, an association unknown until recently.
- 1 July 2015
- Published by Portuguese Society of Dermatology and Venereology in Journal of the Portuguese Society of Dermatology and Venereology
- Vol. 73 (2) , 283-286
Open AccessDERMATIOMIOSITE COM DOENÇA INTERSTICIAL PULMONAR - UMA ASSOCIAÇÃO COM ANTI-MDA-5
Dermatomyositis is a systemic autoimmune disease with cutaneous, muscular and pulmonary involvement. MDA-5 has recently been described as a specific dermatomyositis target antigen associated with a higher risk for interstitial lung disease. A 54-year-old female patient presented with proximal muscular weakness, myalgia and cutaneous signs of dermatomyositis. She presented with high aldolase and CK levels, and the muscular biopsy and electromyography were consistent with dermatomyositis. Pulmonary CT scan showed ground glass appearance. Autoimmunity revealed strong anti-MDA-5 positivity. No neoplasm was detected. She began treatment with prednisolone 20mg, hydroxicloroquine 400mg and methotrexate 20mg/week with very little improvement. She then began IVIG, with better clinical response. The authors report a case of dermatomyositis with interstitial lung disease associated with anti-MDA-5, an association unknown until recently.
- Open Access
- 1 January 2015
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 34 (1) , 17-25
Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes
- 1 January 2015
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 34 (1) , 17-25
Open AccessEconomic evaluation of ticagrelor for secondary prevention following acute coronary syndromes